Skip to main content
Genmab logo

Genmab — Investor Relations & Filings

Ticker · GMAB ISIN · DK0010272202 LEI · 529900MTJPDPE4MHJ122 CO Manufacturing
Open in API
Filings indexed 2,819 across all filing types
Latest filing 2024-01-23 Earnings Release
Country DK Denmark
Listing CO GMAB

About Genmab

https://www.genmab.com/

Genmab is an international biotechnology company that specializes in the creation, development, and commercialization of differentiated antibody therapeutics. The company focuses on transforming the treatment of cancer and other serious diseases. By utilizing proprietary antibody technology platforms and scientific expertise, Genmab develops a pipeline of innovative medicines. Its activities span from discovery and research through clinical development to deliver novel therapies to patients.

Recent filings

Filing Released Lang Actions
Earnings Release 2023
Earnings Release Classification · 1% confidence The document is titled "Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2023" and provides key financial highlights (net sales figures for a specific product for the year 2023) along with company background and contact information. This format—a brief, immediate announcement of key periodic financial results—is characteristic of an Earnings Release (ER). It is not a comprehensive Annual Report (10-K) or an Interim Report (IR), nor is it a transcript (CT) or a presentation (IP). The document is short and focuses on the results themselves, not announcing the publication of a larger report. FY 2023
2024-01-23 English
Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2023
Earnings Release Classification · 1% confidence The document is a short company announcement (under 6,000 characters) regarding the net sales of a specific product (DARZALEX) for the fiscal year 2023. It explicitly labels itself as a 'Company Announcement' and includes a link to an attachment. According to the 'Menu vs Meal' rule, since it is a short announcement of data rather than the full financial report itself, it is classified as a Report Publication Announcement (RPA). FY 2023
2024-01-23 Danish
6-K
Foreign Filer Report
2024-01-23 English
Legal Proceedings Report 2024
Legal Proceedings Report Classification · 1% confidence The document is titled 'Genmab Announces Decision in Arbitration Appeal under License Agreement with Janssen' and is explicitly labeled as a 'Company Announcement'. It details the outcome of a legal/arbitration proceeding concerning a license agreement, which falls under the category of significant corporate events or legal updates. Since it is an announcement about a specific corporate event (legal decision) rather than a routine financial report (like 10-K, IR, ER) or a general regulatory filing (RNS), the most appropriate classification is Legal Proceedings Report (LTR), as it directly relates to significant legal matters involving the company. The document length (6319 chars) is substantial enough that it is not merely an RPA announcing a report, but the report/announcement itself.
2024-01-23 English
Genmab Announces Decision in Arbitration Appeal under License Agreement with Janssen
Legal Proceedings Report Classification · 1% confidence The document is a formal company announcement regarding the outcome of an arbitration appeal involving a license agreement with Janssen. It details the legal decision and its impact (or lack thereof) on financial guidance. Since it concerns a significant legal matter/regulatory outcome and does not fit into specific categories like M&A or financial reporting, it is classified as a Legal Proceedings Report (LTR).
2024-01-23 English
6-K
Foreign Filer Report
2024-01-03 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.